IDiyas

For the Inventor, By the Inventor

Somerset, NJ, United States of America

Richard L Monaghan

USPTO Granted Patents = 28

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 441(Granted Patents)


Location History:

  • Somerset, NJ (US) (1980 - 1996)
  • Morristown, NJ (US) (1995 - 2007)

Company Filing History:

goldMedal28 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1980-2007

Loading Chart...
28 patents (USPTO):Explore Patents
1. 7294646 - Maxi-k channel blockers, methods of use and process for making the same (2007-11-13),
2. 5578581 - Active avermectin analogue (1996-11-26),
3. 5441987 - Antifungal agent (1995-08-15),
4. 5324720 - Methods of achieving antitumor activity using 16-membered-macrolide-type (1994-06-28),
5. 5317031 - Cholesterol lowering compounds (1994-05-31),
6. 5306716 - Methods of achieving antileukemia activity using (1994-04-26),
7. 5278320 - Cholesterol lowering compounds produced by directed biosynthesis (1994-01-11),
8. 5196327 - Process for producing antifungal fermentation products and compositions (1993-03-23),
9. 5019593 - Antifungal fermentation products and compositions thereof (1991-05-28),
10. 5008187 - Antifungal fermentation product (1991-04-16),
11. 4968608 - Process for antifungal fermentation product (1990-11-06),
12. 4847284 - Antifungal fermentation product and derivatives and compositions thereof (1989-07-11),
13. 4828992 - Process for the manufacture of an antifungal antihypercholesterolemic .beta (1989-05-09),
14. 4695544 - Process for the preparation of cholecystokinin antagonists (1987-09-22),
15. 4681846 - Process for the preparation of difficidin and derivative antibacterials (1987-07-21),

Title: An Overview of Richard L Monaghan: Innovator in Ophthalmic and Veterinary Medicine

Introduction: Richard L Monaghan, based in Somerset, NJ, is a prolific inventor with an impressive portfolio of 28 patents. His work primarily focuses on advancements in pharmaceuticals, particularly in the realms of ophthalmic treatments and veterinary medicine.

Latest Patents: Among his latest innovations, Monaghan has developed a patent for "Maxi-k channel blockers, methods of use and process for making the same". This invention is particularly significant as it relates to potent potassium channel blockers formulated for treating glaucoma and other conditions associated with high intraocular pressure in patients' eyes. Additionally, this invention emphasizes the neuroprotective benefits these compounds provide to the eye, highlighting their potential impact on human health. Another notable patent is for an "Active avermectin analogue", specifically the 26-R-Avermectin B.sub.1 a, which is produced via directed biosynthesis. This compound demonstrates effectiveness in the Haemonchus egg to L3 assay, showcasing its relevance in veterinary medicine.

Career Highlights: Richard L Monaghan is an esteemed professional associated with Merck & Company, Inc., a leading pharmaceutical company known for its commitment to innovation in healthcare. His dedication to research and development has significantly contributed to the fields he has focused on, solidifying his status as a key figure in medical advancements.

Collaborations: Throughout his career, Monaghan has collaborated with influential figures in the industry, including Sheldon B Zimmerman and Otto D Hensens. These partnerships highlight the importance of teamwork in driving innovation and creating impactful solutions in medicine.

Conclusion: Richard L Monaghan's contributions to the fields of ophthalmology and veterinary medicine through his inventive work and patents underscore the significance of innovation in improving health outcomes. His continued research and development efforts promise to bring forth further advancements that could change clinical practices in these crucial areas.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…